Rong Guoyi, Fan Wenxin, Shen Jian
Oncology Department, Traditional Chinese Medicine Hospital of Jiulongpo District in Chongqing.
College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing, China.
Medicine (Baltimore). 2019 Jul;98(29):e16520. doi: 10.1097/MD.0000000000016520.
High pretreatment plasma D-dimer levels can predict poor prognosis in various types of gastrointestinal carcinomas. Our meta-analysis explored the correlation between plasma D-dimer levels and prognosis in gastrointestinal malignancies.
Two independent reviewers conducted a comprehensive search from PubMed, ScienceDirect, Embase, Web of Science and the Cochrane Library. All articles evaluating the correlation between pretreatment plasma D-dimer levels and prognosis in gastrointestinal malignancies were searched. We chose overall survival (OS) as the primary survival outcome measure and progression-free survival (PFS), disease-free survival (DFS) and cancer-specific survival (CSS) as the secondary survival outcome measures. We extracted hazard ratios (HRs) and 95% confidence intervals (CIs) from the eligible publications.
We included 30 studies involving 5928 gastrointestinal cancer patients. There was an obvious correlation between high D-dimer levels and poor OS (HR = 2.01, 95% CI = 1.72-2.36, P < .01). High plasma D-dimer levels were correlated with shorter PFS (HR = 1.34, 95% CI = 1.05-1.70, P = .32), DFS (HR = 1.67, 95% CI = 1.12-2.50, P < .01) and CSS rates (HR = 1.93, 95% CI = 1.49-2.49, P = .66).
Elevated pretreatment plasma D-dimer levels might help predict poor prognosis in patients with gastrointestinal malignancies.
治疗前血浆D - 二聚体水平升高可预测各类胃肠道癌的预后不良。我们的荟萃分析探讨了血浆D - 二聚体水平与胃肠道恶性肿瘤预后之间的相关性。
两名独立审阅者对PubMed、ScienceDirect、Embase、Web of Science和Cochrane图书馆进行了全面检索。检索了所有评估治疗前血浆D - 二聚体水平与胃肠道恶性肿瘤预后相关性的文章。我们选择总生存期（OS）作为主要生存结局指标，无进展生存期（PFS）、无病生存期（DFS）和癌症特异性生存期（CSS）作为次要生存结局指标。我们从符合条件的出版物中提取风险比（HRs）和95%置信区间（CIs）。
我们纳入了30项研究，涉及5928例胃肠道癌患者。高D - 二聚体水平与不良OS之间存在明显相关性（HR = 2.01，95%CI = 1.72 - 2.36，P <.01）。高血浆D - 二聚体水平与较短的PFS（HR = 1.34，95%CI = 1.05 - 1.70，P =.32）、DFS（HR = 1.67，95%CI = 1.12 - 2.50，P <.01）和CSS率（HR = 1.93，95%CI = 1.49 - 2.49，P =.66）相关。
治疗前血浆D - 二聚体水平升高可能有助于预测胃肠道恶性肿瘤患者的不良预后。
